OUTCOME AND SAFETY OF RECANALIZATION TREATMENTS IN ISCHEMIC STROKE DUE TO ACUTE BASILAR ARTERY OCCLUSION

July 25, 2022 updated by: NGUYEN THI BICH HUONG, 115 People's Hospital

RECANALISATION THERAPY IN ISCHEMIC STROKE DUE TO BASILAR ARTERY OCCLUSION IN PEOPLE 115 HOSPITAL, VIETNAM

Rationale: Recently, two prospective multicenter RCT reported a potential beneficial effect of endovascular thrombectomy (EVT) in patients with an acute symptomatic basilar artery occlusion (BAO). However, the high rate of crossover in BEST study and the long-term of recruitment in BASICS study influenced the validity of the results.

Objective: To assess the outcomes and prognostic factors of recanalization therapy in patients with BAO, caused by a CTA/MRA/DSA confirmed occlusion of the basilar artery.

Study design: This is a prospective observational study. Study population: Patients with acute ischemic stroke and a confirmed basilar artery occlusion by CTA/MRA/DSA.

Main study parameters/outcomes: Favorable outcome at day 90 defined as a modified Rankin Score (mRS - functional scale) of 0-3. The estimate will be adjusted for the known prognostic variables age, time from onset to treatment, stroke severity (NIHSS), PC ASPECT and collateral flow and adjusted and unadjusted estimates with corresponding 95% confidence intervals will be reported.

Study Overview

Status

Recruiting

Detailed Description

Acute basilar artery thrombosis is associated with a poor prognosis. Prevalence of basilar artery occlusion are not known in Vietnam.Various treatments were tried in groups of patients with acute ischemic stroke due to basilar artery occlusion, but evidence based was not cleared previous studies. Therefore, we conduct this study to evaluate the efficacy and safety of recanalization therapies, which included intravenous thrombosis alone, endovascular alone, or bridging IVT and endovascular, in basilar artery occlusion stroke patients.

Study Type

Observational

Enrollment (Anticipated)

150

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Huy Thang Nguyen

Study Locations

    • Ho Chi Minh City
      • Ho Chi Minh, Ho Chi Minh City, Vietnam, 70000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All patients who were acute ischemic stroke due to basilar artery occlusion admitted People 115 Hospital and treated recanalisation therapies : intravenous tPA, bridging tPA and thrombectomy or thrombectomy alone.

Description

Inclusion Criteria:

  • Symptoms and signs compatible with ischemia in the basilar artery territory.
  • Basilar artery occlusion (BAO) confirmed by CTA or MRA or DSA.
  • Age 18 years or older
  • Patients were treated with one of these among therapies IVT alone, bridging IVT and thrombectomy or thrombectomy alone..

Exclusion Criteria:

  • Patients did not agree to enroll.

Imaging exclusion criteria:

  • High-density lesion consistent with hemorrhage of any degree
  • Significant cerebellar mass effect or acute hydrocephalus

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
favourable outcome
Time Frame: 90 (± 14 days) after procedure
a modified Rankin Score of 0-3
90 (± 14 days) after procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
good outcome
Time Frame: 90 (± 14 days) after procedure
a modified Rankin Score of 0-2
90 (± 14 days) after procedure
mortality
Time Frame: 90 (± 14 days) after procedure
Number of subjects who died at 90-day follow-up/total number of subjects who participated in 90-day follow-up) x100%.
90 (± 14 days) after procedure
Dichotomized mRS score
Time Frame: 90 (± 14 days) after procedure
mRS (0-2 versus 3-6 and 0-4 versus 5-6 )
90 (± 14 days) after procedure
Symptomatic intracerebral hemorrhage (sICH)
Time Frame: within 72 hours after procedure
SICH means any hemorrhage with neurological deterioration, as indicated by an NIHSS score that was higher by ≥4 points than the value at baseline or the lowest value in the first 72 hours or any hemorrhage leading to death.
within 72 hours after procedure
Any intracerebral hemorrhage
Time Frame: within 72 hours after procedure
intracerebral hemorrhage was defined according ECASS definition.
within 72 hours after procedure
Procedural related complications
Time Frame: Perioperative period
arterial perforation, arterial dissection, embolization in a previously uninvolved vascular territory and so on
Perioperative period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Huy Thang Nguyen, Professor, People 115 Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

August 1, 2021

Primary Completion (ANTICIPATED)

December 31, 2023

Study Completion (ANTICIPATED)

December 31, 2023

Study Registration Dates

First Submitted

May 26, 2022

First Submitted That Met QC Criteria

June 1, 2022

First Posted (ACTUAL)

June 2, 2022

Study Record Updates

Last Update Posted (ACTUAL)

July 26, 2022

Last Update Submitted That Met QC Criteria

July 25, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Basilar Artery Occlusion

3
Subscribe